Skip to content

Press Releases

View:
 
Press Releases
All Releases
Mar 28, 2017
Fireside Chat on Tuesday, April 4, 2017 at 1:40 p.m. Eastern Time ANN ARBOR, Mich., March 28, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective and consistent once-daily oral therapies...
Mar 20, 2017
- Global Pivotal Phase 3 Program Design Can Support Approval for an LDL-C Lowering Indication - - Proposed LDL-C Lowering Indication Will Include Patients with High CVD Risk, Specifically Those with ASCVD and/or HeFH - - On Track to Submit NDA for an LDL-C Lowering Indication by 1H 201...
Mar 7, 2017
ANN ARBOR, Mich., March 07, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today announced t...
Mar 6, 2017
Company to Host Webcast on Sunday, March 19, 2017 at 5:30 p.m. Eastern Time ANN ARBOR, Mich., March 06, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral t...
Feb 22, 2017
ANN ARBOR, Mich., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today provided bem...
Feb 15, 2017
Fireside Chat Webcast on Wednesday, February 22, 2017 at 8:00 a.m. Eastern Time ANN ARBOR, Mich., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for ...
Jan 25, 2017
Approximately 2,000 Patients Enrolled Ahead of Schedule Following Study Expansion in October 2016Global Study Enrolled Patients with Hypercholesterolemia with ASCVD and/or HeFH at High CVD RiskTop-Line Results Expected by Q2 2018 ANN ARBOR, Mich., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Esperion Thera...
Jan 9, 2017
ANN ARBOR, Mich., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today announced the initiation of the global...
Jan 8, 2017
Global Phase 3 Program Top-Line Results Expected Mid-2018 ANN ARBOR, Mich., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for the treatment of patients with elevate...
Jan 4, 2017
ANN ARBOR, Mich., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today announced that president and chief executive officer,...
Nov 28, 2016
ANN ARBOR, Mich., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today announced the publication of "Liver-specific ATP-citrate ...
Nov 9, 2016
Presentation and Webcast on Wednesday, November 16, 2016 at 3:00 p.m. Eastern Time ANN ARBOR, Mich., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of patients with elevated low density lipo...
Nov 3, 2016
ANN ARBOR, Mich., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today provided bempedoic acid (ETC-1002) development program upd...
Nov 1, 2016
Presentation and Webcast on Tuesday, November 8, 2016 at 3:00 p.m. Pacific Time/6:00 p.m. Eastern Time ANN ARBOR, Mich., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of patients...
Oct 13, 2016
1002-035 Study Meets Primary Endpoint of Incremental LDL-C Lowering Added to Atorvastatin 80 mgBempedoic Acid Had No Effect on the PK of Atorvastatin and Was Observed to be Safe and Well-Tolerated Conference Call and Webcast on October 13, 2016 at 8:00 a.m. Eastern Time ANN ARBOR...
= add release to Briefcase